Athenex Inc. and its partner Almirall SA have achieved the primary endpoint of 100% clearance of actinic keratosis lesions at Day 57 in two Phase III trials of the topical ointment KX2-391. Data details are yet to be unveiled, but based on earlier trial results the drug is thought to be less efficacious than some marketed therapies. Nevertheless, its ease of administration and favorable local skin reaction profile position it well to take market share.
Good Prospects For Athenex/Almirall Following PhIII Actinic Keratosis Results
Two Phase III studies of KX2-391 to treat actinic keratosis of the face and scalp met their primary endpoint of 100% clearance. The treatment could prove more convenient than marketed therapies.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.